OCRELIZUMAB

62729 reported adverse events

Drug classes: CD20-directed Cytolytic Antibody [EPC]

These side effects are most commonly reported by patients taking OCRELIZUMAB:

# Side effect Count
0 COVID-19 11587
1 FATIGUE 6297
2 URINARY TRACT INFECTION 3818
3 HEADACHE 3311
4 MULTIPLE SCLEROSIS 3123
5 MULTIPLE SCLEROSIS RELAPSE 2818
6 GAIT DISTURBANCE 2756
7 ASTHENIA 2735
8 NASOPHARYNGITIS 2601
9 PAIN 2585
See all common reactions for OCRELIZUMAB

OCRELIZUMAB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SARS-COV-2 ANTIBODY TEST NEGATIVE 262 0.5470
1 MAGNETIC RESONANCE IMAGING SPINAL ABNORMAL 63 0.5164
2 CD19 LYMPHOCYTES DECREASED 62 0.4769
3 JC POLYOMAVIRUS TEST POSITIVE 557 0.4757
4 B-LYMPHOCYTE COUNT INCREASED 71 0.3817
5 RELAPSING MULTIPLE SCLEROSIS 114 0.3775
6 B-LYMPHOCYTE COUNT DECREASED 509 0.3737
7 B-LYMPHOCYTE ABNORMALITIES 47 0.3287
8 MULTIPLE SCLEROSIS PSEUDO RELAPSE 89 0.2625
9 PARANASAL SINUS MUCOSAL HYPERTROPHY 26 0.2185
See all enriched reactions for OCRELIZUMAB